Global Acute Respiratory Distress Syndrome Market to 2030 - Insight, Epidemiology and Forecast
Dublin, Dec. 09, 2020 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast -2030" drug pipelines has been added to *ResearchAndMarkets.com's* offering.This report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, France, Italy, and United Kingdom) and Japan.
The Acute Respiratory Distress Syndrome (ARDS) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Respiratory Distress Syndrome (ARDS) market size from 2017 to 2030. The report also covers current Acute Respiratory Distress Syndrome (ARDS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
*Acute Respiratory Distress Syndrome (ARDS) Diagnosis*
The diagnosis of Acute Respiratory Distress Syndrome (ARDS) is based on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests.
ARDS is characterized by an acute, diffuse, inflammatory lung injury, leading to increased alveolar-capillary permeability, increased lung weight, and loss of aerated lung tissue. Clinically, this establishes as hypoxemia, with bilateral opacities on chest radiography, associated with reduced lung compliance and increased venous admixture and physiological dead space. Morphologically, diffuse alveolar damage is observed in the acute phase of ARDS.
*Acute Respiratory Distress Syndrome (ARDS) Treatment*
The Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition, was described as a form of respiratory failure that closely resembled respiratory distress syndrome in infants. This can be caused by a variety of pulmonary (such as pneumonia, aspiration) or non-pulmonary (like sepsis, pancreatitis, and trauma) abuses, leading to the development of non-hydrostatic pulmonary edema. The treatment of ARDS involves general supportive measures, ventilator strategies, and appropriate treatment of the underlying condition. Besides general supportive measures, pharmacological interventions are commonly considered throughout ARDS. Although research involving the investigation of drug candidates is being carried out for over a decade, only a few pharmacological therapies have emerged for ARDS.
Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management. There are relatively few treatments available for ARDS. Other treatment options, which the patients with ARDS are generally subjected include supplemental oxygen, prone positioning, use of paralytics, fluid management, and a technique called positive end-expiratory pressure (PEEP) to help push the fluid out of air sacs. These are combined with continuing treatment of the original illness or injury. Because people with ARDS are less able to fight lung infections, they may develop bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also, supportive treatment, such as intravenous fluid or food, may be needed.
It covers the details of conventional and current medical therapies available in the Acute Respiratory Distress Syndrome (ARDS) market for the treatment of the various types of Acute Respiratory Distress Syndrome (ARDS). It also provides the treatment guidelines and algorithms of the United States and Europe. The Acute Respiratory Distress Syndrome (ARDS) market report gives a thorough understanding of Acute Respiratory Distress Syndrome (ARDS) by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.
*Acute Respiratory Distress Syndrome (ARDS) Epidemiology*
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of ARDS, Severity-specific Incidence of ARDS, and Incidence of ARDS by Risk Factors scenario of Acute Respiratory Distress Syndrome (ARDS) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
*Key Findings*
· In the 7MM, the total incident population of ARDS is estimated to be 799,872, in 2017.
· Generally, the highest number of incident cases were assessed for ARDS due to Pneumonia, in all the 7MM countries, except the United Kingdom, in which Sepsis was the primary risk factor for ARDS.
· Due to occurrence of COVID-19, there is a sudden increase in the cases of ARDS in the US, from 495,655 in 2
*Report Highlights*
· Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is anticipated to rise in the forecasted period (2017-2030).
· The market for ARDS in the 7MM is projected to rise during the study period (2017-2030).
· Dynamic research and developmental activity with 60+ companies in the pipeline at different stages.
· In the coming years, Acute Respiratory Distress Syndrome (ARDS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
· The companies and academics are working to assess challenges and seek opportunities that could influence Acute Respiratory Distress Syndrome (ARDS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
· Major players are involved in developing therapies for Acute Respiratory Distress Syndrome (ARDS). Launch of emerging therapies will significantly impact the Acute Respiratory Distress Syndrome (ARDS) market.
· The in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
*Reasons to Buy*
· The report will help in developing business strategies by understanding trends shaping and driving the Acute Respiratory Distress Syndrome (ARDS).
· To understand the future market competition in the ARDS market and Insightful review of the key market drivers and barriers.
· Organize sales and marketing efforts by identifying the best opportunities for Acute Respiratory Distress Syndrome (ARDS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
· Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
· Organize sales and marketing efforts by identifying the best opportunities for Acute Respiratory Distress Syndrome (ARDS) market.
· To understand the future market competition in the Acute Respiratory Distress Syndrome (ARDS) market.
*List of Companies*
· Faron Pharmaceuticals
· PhaseBio Pharmaceuticals
· Sage Therapeutics
· Chimerix
· Direct Biologics
· Kiniksa Pharmaceuticals
· Pluristem Therapeutics
· Alexion Pharmaceuticals
· Biomarck Pharmaceuticals
· Athersys
· Veru
· Apeptico Forschung und Entwicklung GmbH
· Alexion Pharmaceuticals
· Humanigen, Inc.
· Roche Pharma AG
· Alexion
· Mylan Laboratories
· Vanda Pharmaceuticals Inc.; the University of Illinois at Chicago
· Laboratoire francais de Fractionnement et de Biotechnologies
· Ache Laboratorios Farmaceuticos
· Implicit Bioscience
· Alexion
· NeuroRx/Relief Therapeutics
· CytoDyn
· Kiniksa
· Biohaven Pharmaceutical Holding Co. Ltd.
· Kinevant Sciences GmbH/Roivant Sciences
· Iltoo Pharma
· Eli Lilly and Company
· Merck/Eli Lilly
· Apeiron Biologics
· Roche AG
· And Many More Companies!
*Key Topics Covered:*
*1 Key Insights*
*2 Executive Summary*
*3 Acute Respiratory Distress Syndrome (ARDS): Market Overview at a Glance*
3.1 Total Market Share (%) Distribution of ARDS in 2017
3.2 Total Market Share (%) Distribution of ARDS in 2030
*4 Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview*
4.1 Introduction
4.2 Causes and Risk Factors
4.2.1 Risk Factors of Acute Respiratory Distress Syndrome (ARDS)
4.3 Pathophysiology of Acute Respiratory Distress Syndrome (ARDS)
4.3.1 Inflammatory Processes in ARDS
4.3.2 The initial event of injury
4.3.3 Endothelial Damage
4.3.4 Specific Mediators of Inflammation and Lung Damage in ARDS
4.3.5 Altered Pulmonary Physiology in ARDS
4.3.6 Genetics
4.4 Stages of Acute Respiratory Distress Syndrome (ARDS)
4.5 Ventilator-Induced Lung Injury (VILI)
4.6 Major Determinants of VILI
4.6.1 Ventilator determinants of VILI
4.6.2 Patient determinants of VILI
4.7 Diagnosis of Acute Respiratory Distress Syndrome (ARDS)
4.7.1 Imaging techniques in ARDS
4.7.2 Imaging findings in ARDS
4.7.3 Differential Diagnosis
*5 Case Reports*
5.1 Coronavirus Disease 2019 (COVID-19) Complicated by Acute Respiratory Distress Syndrome: An Internist's Perspective
5.2 A fulminant case of Acute Respiratory Distress Syndrome associated with mycoplasma pneumonia treated with nasal high-flow oxygen therapy
5.3 A case report of severe hypothermia complicated by acute respiratory distress syndrome
*6 Epidemiology and Patient Population*
6.1 Key Findings
6.2 Methodology
*7 7MM Epidemiology Analysis*
7.1 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM
7.2 Severity-specific Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM
*8 United States Epidemiology*
8.1 Assumptions and Rationale
8.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United States
8.3 Severity-specific Incident Population of ARDS in the United States
8.4 Incident Population of ARDS by Risk Factors in the United States
*9 EU5 Epidemiology*
9.1 Germany Epidemiology
9.2 France Epidemiology
9.3 Italy Epidemiology
9.4 Spain Epidemiology
9.5 United Kingdom Epidemiology
*10 Japan Epidemiology*
10.1 Assumptions and Rationale
10.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS), ARDS in Japan
10.3 Severity-specific Incidence of ARDS in Japan
10.4 Incident Population of ARDS by Risk Factors in Japan
*11 Treatment Algorithm, Current Treatment, and Medical Practices*
11.1 Treatment and Support for Acute Respiratory Distress Syndrome (ARDS)
11.2 Treatment of ALI/ARDS associated with COVID-19
*12 Proposed Guidelines for ARDS*
12.1 An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome
12.2 The Clinical Practice Guideline by the Japanese Society of Respiratory Care Medicine and the Japanese Society of Intensive Care Medicine for the management of ARDS in Japan
12.3 Infectious Diseases Society of America (IDSA) Guidelines on the Treatment and Management of Patients with COVID-19
12.4 WHO guidance for the treatment ARDS associated with COVID-19
*13 Unmet Needs*
*14 Off-Label Therapies for ARDS*
14.1 Neuromuscular Blocking Agents (NMBAs)
14.2 Inhaled Vasodilators
14.3 Corticosteroids
*15 Emerging Therapies*
15.1 Key Cross Competition
15.2 Traumakine: Faron Pharmaceuticals
15.3 Bio-11006: BioMarck Pharmaceuticals
15.4 MultiStem: Athersys
15.5 Solnatide (AP301): APEPTICO Forschung und Entwicklung GmbH
15.6 Ultomiris (ravulizumab-cwvz): Alexion Pharma
15.7 Soliris (eculizumab): Alexion Pharma
*16 Unknown Status*
16.1 Ulinastatin: Techpool Bio-Pharma
16.1.1 Product Description
16.1.2 Other Developmental Activities
16.1.3 Clinical Development
16.1.4 Clinical Trials Information
16.1.5 Product Profile
*17 COVID-19 associated with ARDS: Emerging Drugs*
17.1 L-citrulline: Asklepion Pharmaceuticals
17.2 Cholecalciferol: Mylan Laboratories
17.3 Ruxolitinib: Incyte Corporation/Novartis
17.4 BDB-001: Staidson (Beijing) Biopharmaceuticals
17.5 RLF-100 (aviptadil): NeuroRx/Relief Therapeutics
17.6 Zavegepant/Vazegepant: Biohaven Pharmaceutical
17.7 Metablok (LSALT peptide): Arch Biopartners
17.8 Lenzilumab: Humanigen
17.9 Actemra/RoActemra (Tocilizumab): Roche Pharma AG
17.10 DSTAT (Dociparastat sodium): Chimerix
17.11 Pemziviptadil (PB1046): PhaseBio Pharmaceuticals
17.12 ExoFlo (DB-001): Direct Biologics
17.13 Veru-111: Veru
17.14 Tradipitant: Vanda Pharmaceuticals
17.15 Brexanolone: Sage Therapeutics
17.16 Mavrilimumab: Kiniksa Pharmaceuticals
17.17 Human immunoglobulin: Laboratoire francais de Fractionnement et de Biotechnologies (LFB)
17.18 Remestemcel-L: Mesoblast Limited
17.19 PLX-PAD: Pluristem Therapeutics
17.20 CERC-002: Cerecor
17.21 TD-0903: Theravance Biopharma
17.22 ILT101: ILTOO Pharma
*18 Discontinued Products*
18.1 APN01 (GSK2586881): Apeiron Biologics/GlaxoSmithKline
18.2 GSK2862277: GlaxoSmithKline
18.3 Remodulin (Treprostinil Inhalation Solution): United Therapeutics
*19 Acute Respiratory Distress Syndrome (ARDS): 7MM Market Analysis*
19.1 Key Findings
19.2 Current Market Size: Forecast Assumptions
19.3 Market Size of ARDS in the 7MM countries
19.4 Market Size of ARDS by therapies in the 7MM
*20 Attribute Analysis*
*21 Key Emerging Therapies: Market Forecast Assumptions*
*22 United States: Market Outlook*
*23 EU-5 Countries: Market Outlook*
*24 Japan Market Outlook*
*25 Access and Reimbursement*
*26 Market Drivers*
*27 Market Barriers*
*28 SWOT Analysis*
*29 Appendix*
29.1 Report Methodology
*30 Publisher Capabilities*
*31 Disclaimer*
*32 About the Publisher*
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/r3zkt4
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900